The combination of conventional chemotherapeutic drugs with inhibitors of Aurora-A kinase activity represents a promising therapeutic strategy for the management of chemoresistant breast cancer, particularly TNBCs that currently lack FDA-approved targeted therapies. This evidence concerns the gene AURKA and breast carcinoma.